Results 181 to 190 of about 7,834 (208)

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of Oncology, 2020
Natasha Woodward
exaly  

A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies

European Journal of Cancer, 2020
Alberto S Pappo, Olivia Campagne, Clinton F Stewart   +2 more
exaly  

Summary of opinion: Talzenna,talazoparib

Case Medical Research, 2019
openaire   +2 more sources

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

International Journal of Molecular Sciences, 2022
Ziba Sabet, Dimitrios Vagiannis, Youssif Budagaga   +2 more
exaly  

Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials

Journal of Clinical Pharmacology, 2020
Mohamed Elmeliegy, Yanke Yu, Jennifer K Litton   +2 more
exaly  

Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial

Journal of Clinical Pharmacology, 2020
Yanke Yu, Mohamed Elmeliegy, Jennifer K Litton   +2 more
exaly  

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Case Medical Research, 2019
openaire   +1 more source

<p>Evidence to date: talazoparib in the treatment of breast cancer</p>

OncoTargets and Therapy, 2019
Romualdo Barroso-Sousa, Sara M Tolaney
exaly  

Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

Oncologist, 2020
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo   +2 more
exaly  

Olaparib/talazoparib

Reactions Weekly
openaire   +1 more source